Cargando…
Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan
BACKGROUND: Previous SARS-CoV-2 infection and vaccination, coupled to rapid evolution of SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We characterized clinical symptoms of COVID-19 individuals in omicron BA.2 and BA.5 Japanese pandemic periods to identify omicron and subvaria...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934721/ https://www.ncbi.nlm.nih.gov/pubmed/36798223 http://dx.doi.org/10.1101/2023.02.02.23285393 |
_version_ | 1784889934090338304 |
---|---|
author | Nakakubo, Sho Kishida, Naoki Okuda, Kenichi Kamada, Keisuke Iwama, Masami Suzuki, Masaru Yokota, Isao Ito, Yoichi M. Nasuhara, Yasuyuki Boucher, Richard C. Konno, Satoshi |
author_facet | Nakakubo, Sho Kishida, Naoki Okuda, Kenichi Kamada, Keisuke Iwama, Masami Suzuki, Masaru Yokota, Isao Ito, Yoichi M. Nasuhara, Yasuyuki Boucher, Richard C. Konno, Satoshi |
author_sort | Nakakubo, Sho |
collection | PubMed |
description | BACKGROUND: Previous SARS-CoV-2 infection and vaccination, coupled to rapid evolution of SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We characterized clinical symptoms of COVID-19 individuals in omicron BA.2 and BA.5 Japanese pandemic periods to identify omicron and subvariant associations between symptoms, immune status, and clinical outcomes. METHODS: Individuals registered in Sapporo’s web-based COVID-19 information system entered 12 pre-selected symptoms, days since symptom onset, vaccination history, SARS-CoV-2 infection history, and background. Symptom frequencies, variables associated with symptoms, and symptoms associated with progression to severe disease were analysed. RESULTS: For all omicron-infected individuals, cough was the most common symptom (62.7%), followed by sore throat (60.7%), nasal discharge (44.3%), and fever (38.8%). Omicron BA.5 infection was associated with a higher symptom burden than BA.2 in vaccinated and unvaccinated individuals. Omicron breakthrough-infected individuals with ≥ 3 vaccinations or previous infection were less likely to exhibit systemic symptoms, but more likely to exhibit upper respiratory symptoms. Infected elderly individuals had lower odds for all symptoms, but, when symptoms were manifest, systemic symptoms were associated with an increased risk, whereas upper respiratory symptoms with a decreased risk, of severe disease. CONCLUSION: Host immunological status, omicron subvariant, and age were associated with a spectrum of COVID-19 symptoms and outcomes. BA.5 produced a greater symptom burden than BA.2. Vaccination and prior infection mitigated systemic symptoms and improved outcomes, but increased upper respiratory tract symptom burden. Systemic, but not upper respiratory, symptoms in the elderly heralded severe disease. |
format | Online Article Text |
id | pubmed-9934721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-99347212023-02-17 Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan Nakakubo, Sho Kishida, Naoki Okuda, Kenichi Kamada, Keisuke Iwama, Masami Suzuki, Masaru Yokota, Isao Ito, Yoichi M. Nasuhara, Yasuyuki Boucher, Richard C. Konno, Satoshi medRxiv Article BACKGROUND: Previous SARS-CoV-2 infection and vaccination, coupled to rapid evolution of SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We characterized clinical symptoms of COVID-19 individuals in omicron BA.2 and BA.5 Japanese pandemic periods to identify omicron and subvariant associations between symptoms, immune status, and clinical outcomes. METHODS: Individuals registered in Sapporo’s web-based COVID-19 information system entered 12 pre-selected symptoms, days since symptom onset, vaccination history, SARS-CoV-2 infection history, and background. Symptom frequencies, variables associated with symptoms, and symptoms associated with progression to severe disease were analysed. RESULTS: For all omicron-infected individuals, cough was the most common symptom (62.7%), followed by sore throat (60.7%), nasal discharge (44.3%), and fever (38.8%). Omicron BA.5 infection was associated with a higher symptom burden than BA.2 in vaccinated and unvaccinated individuals. Omicron breakthrough-infected individuals with ≥ 3 vaccinations or previous infection were less likely to exhibit systemic symptoms, but more likely to exhibit upper respiratory symptoms. Infected elderly individuals had lower odds for all symptoms, but, when symptoms were manifest, systemic symptoms were associated with an increased risk, whereas upper respiratory symptoms with a decreased risk, of severe disease. CONCLUSION: Host immunological status, omicron subvariant, and age were associated with a spectrum of COVID-19 symptoms and outcomes. BA.5 produced a greater symptom burden than BA.2. Vaccination and prior infection mitigated systemic symptoms and improved outcomes, but increased upper respiratory tract symptom burden. Systemic, but not upper respiratory, symptoms in the elderly heralded severe disease. Cold Spring Harbor Laboratory 2023-02-07 /pmc/articles/PMC9934721/ /pubmed/36798223 http://dx.doi.org/10.1101/2023.02.02.23285393 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Nakakubo, Sho Kishida, Naoki Okuda, Kenichi Kamada, Keisuke Iwama, Masami Suzuki, Masaru Yokota, Isao Ito, Yoichi M. Nasuhara, Yasuyuki Boucher, Richard C. Konno, Satoshi Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan |
title | Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan |
title_full | Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan |
title_fullStr | Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan |
title_full_unstemmed | Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan |
title_short | Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan |
title_sort | associations of covid-19 symptoms with omicron subvariants ba.2 and ba.5, host status, and clinical outcomes: a registry-based observational study in sapporo, japan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934721/ https://www.ncbi.nlm.nih.gov/pubmed/36798223 http://dx.doi.org/10.1101/2023.02.02.23285393 |
work_keys_str_mv | AT nakakubosho associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan AT kishidanaoki associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan AT okudakenichi associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan AT kamadakeisuke associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan AT iwamamasami associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan AT suzukimasaru associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan AT yokotaisao associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan AT itoyoichim associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan AT nasuharayasuyuki associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan AT boucherrichardc associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan AT konnosatoshi associationsofcovid19symptomswithomicronsubvariantsba2andba5hoststatusandclinicaloutcomesaregistrybasedobservationalstudyinsapporojapan |